Implantable device aims to target pancreatic tumors with fewer side effects
NCT ID NCT07481383
Summary
This early-stage study is testing the safety of a new implantable device that delivers chemotherapy directly to pancreatic tumors. The device is placed on the pancreas during surgery and releases the drug gemcitabine locally, aiming to target the cancer more precisely and potentially reduce side effects compared to standard IV chemotherapy. The study will enroll 12 people with non-metastatic, non-removable pancreatic cancer who have already completed initial chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA NON-RESECTABLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West Virginia University
RECRUITINGMorgantown, West Virginia, 26506, United States
Contact
Conditions
Explore the condition pages connected to this study.